Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222702 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)
A Phase 2 study of Clostridium Difficile Infection, sponsored by Actelion.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT01222702: Completed Phase 2 study of Clostridium Difficile Infection, sponsored by Actelion.
NCT01222702 is a Phase 2 study of Clostridium Difficile Infection that has completed, run by Actelion. The registered enrollment target is 84 participants, below the 12,059-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01222702, a Phase 2 study of Clostridium Difficile Infection, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
Cadazolid is a new antibiotic developed for the treatment of Clostridiun difficile associated diarrhea (CDAD), also known as Clostridium Difficile Infection (CDI). The purpose of the study was to evaluate the efficacy and safety of different doses of cadazolid in order to find the dose of cadazolid to be used for further clinical development of the compound in subjects with CDAD.
Primary Outcome
Percentages of subjects with clinical cure are calculated, with clinical cure being defined as resolution of diarrhea with no further Clostridium Difficile-associated diarrhea (CDAD) treatment required at test-of-cure (TOC) visit. Resolution of diarrhea was defined as the occurrence of ≤ 2 semi-formed or formed stools during 24 h for at least 2 consecutive 24 h periods.
Conditions Studied
Interventions
- DRUG Vancomycin
- DRUG Cadazolid
- DRUG Placebo-matching cadazolid
- DRUG Placebo-matching vancomycin
Study Locations (20)
Other
- Clinical Ivestigative Site 6602 - Calgary
- Clinical Investigative Site 6632 - Cologne
- Clinical Investigative Site 6633 - Regensburg
- Clinical Investigative Site 6634 - Ulm
- Clinical Investigative Site 6734 - Busto Arsizio
- Clinical Investigative Site 6735 - Modena
Florida
- Clinical Investigative Site 6919 - Jacksonville
- Clinical Investigative Site 6938 - Orlando
Georgia
- Clinical Investigative Site 6930 - Decatur
- Clinical Investigative Site 6935 - Marietta
Quebec
- Clinical Investigative Site 6601 - Montreal
- Clinical Investigative Site 6606 - Sherbrooke
Delaware
- Clinical Investigative Site 6902 - Newark
Idaho
- Clinical Investigative Site 6915 - Idaho Falls
Illinois
- Clinical Investigative Site 6906 - Chicago
Massachusetts
- Clinical Investigative Site 6917 - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2011-01-25 |
| Est. Completion | 2012-11-12 |
| Phase | Phase 2 |
What the finished NCT01222702 record still lists
NCT01222702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 12,059-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Clostridium Difficile Infection appearing as the primary indexed condition, and to 4 interventions - of which Vancomycin is the first listed.
NCT01222702 names 20 study sites across 12 states, led by Other, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT01222702 about?
NCT01222702 is a clinical study titled "Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)". Cadazolid is a new antibiotic developed for the treatment of Clostridiun difficile associated diarrhea (CDAD), also known as Clostridium Difficile Infection (CDI). The purpose of the study was to evaluate the efficacy and safety of different doses of cadazolid in order to find the dose of cadazolid ...
What is the current status of trial NCT01222702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2011-01-25. Estimated completion is 2012-11-12.
What conditions does trial NCT01222702 study?
This clinical trial studies the following conditions: Clostridium Difficile Infection.
What interventions are being tested in trial NCT01222702?
The interventions under investigation include: Vancomycin (DRUG), Cadazolid (DRUG), Placebo-matching cadazolid (DRUG), Placebo-matching vancomycin (DRUG).
Who is sponsoring clinical trial NCT01222702?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01222702 being conducted?
This trial has 20 study locations across Delaware, Florida, Georgia, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridium Difficile Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01222702's enrollment target sits among peer trials
84 12th of 13 higher than 2 of 13 other Clostridium Difficile Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Clostridium Difficile Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
RECRUITING · Phase 2
-
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
RECRUITING · Phase 2
-
The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation
COMPLETED · Phase 2
-
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
COMPLETED · Phase 2
-
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
COMPLETED · Phase 2
-
Study of CB-183,315 in Participants With Clostridium Difficile Infection
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI